Clinical Trial Update: SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating SHR-1210 in combination with apatinib for metastatic, persistent, or recurrent cervical cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent Cervical Carcinoma, Metastatic Cervical Cancer | Phase 2 | Status: COMPLETED